Cybin (CYBN) Competitors $7.17 -0.43 (-5.66%) Closing price 04:00 PM EasternExtended Trading$7.16 0.00 (-0.07%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CYBN vs. GHRS, DNA, NAGE, TNGX, STOK, VIR, AMLX, DAWN, DNTH, and KALVShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include GH Research (GHRS), Ginkgo Bioworks (DNA), Niagen Bioscience (NAGE), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Vir Biotechnology (VIR), Amylyx Pharmaceuticals (AMLX), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Its Competitors GH Research Ginkgo Bioworks Niagen Bioscience Tango Therapeutics Stoke Therapeutics Vir Biotechnology Amylyx Pharmaceuticals Day One Biopharmaceuticals Dianthus Therapeutics KalVista Pharmaceuticals GH Research (NASDAQ:GHRS) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends. Which has better earnings and valuation, GHRS or CYBN? GH Research is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-17.26CybinN/AN/A-$57.88M-$3.88-1.85 Is GHRS or CYBN more profitable? GH Research's return on equity of -16.71% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% Cybin N/A -37.58%-36.59% Do analysts recommend GHRS or CYBN? GH Research currently has a consensus price target of $32.00, indicating a potential upside of 150.59%. Cybin has a consensus price target of $85.00, indicating a potential upside of 1,085.50%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals & insiders have more ownership in GHRS or CYBN? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, GHRS or CYBN? GH Research has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Does the media refer more to GHRS or CYBN? In the previous week, GH Research had 4 more articles in the media than Cybin. MarketBeat recorded 7 mentions for GH Research and 3 mentions for Cybin. GH Research's average media sentiment score of 1.07 beat Cybin's score of 0.24 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGH Research beats Cybin on 10 of the 14 factors compared between the two stocks. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$169.14M$791.77M$5.62B$21.05BDividend YieldN/A4.84%4.61%3.56%P/E Ratio-1.641.1830.2928.03Price / SalesN/A26.06463.4157.07Price / CashN/A19.5638.2123.95Price / Book0.666.588.825.26Net Income-$57.88M-$4.98M$3.25B$994.11M7 Day Performance-5.53%3.87%4.05%2.10%1 Month Performance-4.02%-0.29%4.32%0.99%1 Year PerformanceN/A19.81%36.25%15.24% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin2.6131 of 5 stars$7.17-5.7%$85.00+1,085.5%N/A$169.14MN/A-1.6450News CoveragePositive NewsGHRSGH Research3.038 of 5 stars$13.44-2.2%$32.00+138.1%+23.7%$714.87MN/A-17.0110News CoveragePositive NewsEarnings ReportAnalyst RevisionDNAGinkgo Bioworks1.0028 of 5 stars$13.62+11.7%$8.50-37.6%N/A$713.50M$227.04M-1.49640Earnings ReportGap DownNAGENiagen Bioscience1.3708 of 5 stars$9.64+6.6%$13.22+37.1%N/A$712.08M$99.60M56.71120News CoverageAnalyst ForecastAnalyst RevisionTNGXTango Therapeutics2.0853 of 5 stars$6.59+0.9%$10.50+59.3%-24.0%$707.81M$40.99M-5.4090Positive NewsAnalyst RevisionGap DownSTOKStoke Therapeutics4.1246 of 5 stars$13.14+1.8%$25.80+96.3%+19.3%$704.85M$36.56M16.63100Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap DownVIRVir Biotechnology3.2062 of 5 stars$5.10+1.4%$30.25+493.1%-46.2%$695.34M$74.21M-1.21580Analyst RevisionGap DownAMLXAmylyx Pharmaceuticals3.3343 of 5 stars$7.96+3.1%$11.75+47.6%+317.1%$687.72M-$1.27M-2.56200News CoverageEarnings ReportDAWNDay One Biopharmaceuticals2.6071 of 5 stars$6.74+1.4%$29.00+330.3%-53.7%$674.06M$131.16M-9.4960DNTHDianthus Therapeutics1.1871 of 5 stars$21.50+4.4%$53.00+146.5%-21.2%$662.17M$6.24M-7.4780News CoverageEarnings ReportAnalyst RevisionKALVKalVista Pharmaceuticals4.0836 of 5 stars$13.31+0.8%$26.29+97.5%-3.0%$659.89MN/A-3.61100 Related Companies and Tools Related Companies GHRS Competitors DNA Competitors NAGE Competitors TNGX Competitors STOK Competitors VIR Competitors AMLX Competitors DAWN Competitors DNTH Competitors KALV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CYBN) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access